In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The secondary preventive heart school intervention and long-term outcome after myocardial infarction

Session Cardiovascular rehabilitation revisited

Speaker John Wallert

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Cardiovascular Rehabilitation
  • Session type : Abstract Session
  • FP Number : 223

Authors : J Wallert (Uppsala,SE), E Olsson (Uppsala,SE), F Norlund (Uppsala,SE), R Pingel (Uppsala,SE), M Leosdottir (Malmö,SE), G Burell (Uppsala,SE), C Held (Uppsala,SE)


J. Wallert1 , E. Olsson1 , F. Norlund1 , R. Pingel2 , M. Leosdottir3 , G. Burell2 , C. Held4 , 1Uppsala University, Department of Women's and Children's Health - Uppsala - Sweden , 2Uppsala University, Department of Public Health and Caring Sciences - Uppsala - Sweden , 3Skåne University Hospital, Department of Cardiology - Malmö - Sweden , 4Uppsala Clinical Research Center, Department of Medical Sciences: Cardiology - Uppsala - Sweden ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 21

Background: The heart school is an educational intervention offered in comprehensive cardiac rehabilitation (CR) in Sweden after suffering myocardial infarction (MI). The intervention aims to reduce modifiable risk factors and thereby also mortality and morbidity post-MI, yet has not been investigated with respect to hard endpoints.

Purpose: We estimated the association of attending the heart school with both all-cause and cardiovascular (CV) mortality, two and five years after admission.

Methods: This observational study identified patients with first-time MI as consecutively registered in the nationwide Swedish heart registry, SWEDEHEART (2006–2015), and were followed up using the Cause of Death registry for outcome events with minimal (<1%) loss to follow-up. Socioeconomic data was acquired from Statistics Sweden. The exposure was attending heart school as registered at first CR visit 6–10 weeks post-MI. Of 192059 MI admissions, 47316 unique patients with first-time MI who attended the first CR visit were identified as the study population (63.1 years, 24% females, 41% heart school attendees). Propensity score matching of treated patients with controls on 25 covariates was performed after multiple imputation. The association between heart school attendance and outcomes was estimated with Cox regression and survival curves in the matched sample. Several sensitivity analyses were conducted.

Results: In the matched sample, during the two and five year follow-up 493 and 1281 deaths by all-causes, of which 228 and 483 were cardiovascular deaths, occurred. The main analysis showed that attending heart school was associated with a lower risk of both all-cause (2-year HR = 0.53 [0.44, 0.64]; 5-year HR = 0.62 [0.55, 0.69]), and CV (0.50 [0.38, 0.65]; 0.57 [0.47, 0.69]) mortality. Results were similar in sensitivity analyses, including (a) landmark analysis conditioning on survivors 30, 60, 90, and 120 days post-MI, (b) after additional matching on other components of CR, and (c) in the male, female, <65 years, and 65–75 year old strata. See the figure for the stratified analysis with 5-year all-cause mortality.

Conclusion: Our results from this nationwide registry study indicate that attending heart school as part of CR, was associated with an almost halved all-cause and CV mortality in patients with first-time MI. These results warrant further investigation through adequately powered randomised trials.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are